Last update Oct. 17, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Pioglitazone Hydrochloride in other languages or writings:
Pioglitazone Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Pioglitazone Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 80 | % |
Molecular weight | 393 | daltons |
Protein Binding | > 99 | % |
VD | 0.6 ± 0.4 | l/Kg |
pKa | 6.7 | - |
Tmax | 2 | hours |
T½ | 3 - 7 (Metab: 6 - 24) | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Pioglitazone is a thiazolidinedione used in conjunction with diet and exercise to normalize blood glucose levels in adults with type 2 diabetes mellitus. It is administered orally once daily.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (very high percentage of binding to plasma proteins and large volume of distribution) make it very unlikely to pass into breast milk in clinically significant quantities.
Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Some health agencies (France, Germany) have recommended the suspension of marketing of pioglitazone for being associated with an increased risk of cancer of the bladder. (IARC 2016)
Thiazolidinediones increase insulin sensitivity. Oral antidiabetics are not useful in type 1 diabetes. In type 2 diabetes, diet, exercise and breastfeeding will improve blood glucose levels.
See below the information of this related product: